- call +1-201-465-4211
- email sales@mrinsights.biz
IBS‑C is defined as belly pain (abdominal pain) associated with constipation. The symptoms of IBS‑C are defined as long-lasting and keep coming back. Those suffering from IBS‑C also have hard or lumpy stools at least 25% of the time, and loose or watery stools less than 25% of the time.
Scope of the Report:
The important driver increasing growth in the Global Irritable Bowel Syndrome with Constipation drugs Market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation include high intake of foods like insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and this loss of water through urination can also lead to IBS.
The worldwide market for IBS-C Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the IBS-C Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma
Astellas Pharmaceuticals
Ardelyx
Synthetic Biologics
Teva Pharmaceutical Industries
Bama-Geve
Ferring BV
Ironwood Pharmaceuticals
Salix Pharmaceuticals
Norgine
Prometheus Laboratories
Actavis Nordic
Albireo Pharma
Yuhan Corp
Astrazeneca
The Menarini Group
Ono Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
There are 15 Chapters to deeply display the global IBS-C Drug market.
Chapter 1, to describe IBS-C Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of IBS-C Drug, with sales, revenue, and price of IBS-C Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of IBS-C Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, IBS-C Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe IBS-C Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 IBS-C Drug Introduction
1.2 Market Analysis by Type
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Osmotic Laxatives
1.2.4 Stimulant Laxatives
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Catalent Pharmaceuticals Solutions
2.1.1 Business Overview
2.1.2 IBS-C Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Nestle
2.2.1 Business Overview
2.2.2 IBS-C Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Nestle IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Abbott Laboratories
2.3.1 Business Overview
2.3.2 IBS-C Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Abbott Laboratories IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Synergy Pharmaceuticals
2.4.1 Business Overview
2.4.2 IBS-C Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Synergy Pharmaceuticals IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Sucampo Pharmaceuticals
2.5.1 Business Overview
2.5.2 IBS-C Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sucampo Pharmaceuticals IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Novartis Pharma
2.6.1 Business Overview
2.6.2 IBS-C Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Novartis Pharma IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Astellas Pharmaceuticals
2.7.1 Business Overview
2.7.2 IBS-C Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Astellas Pharmaceuticals IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Ardelyx
2.8.1 Business Overview
2.8.2 IBS-C Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Ardelyx IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Synthetic Biologics
2.9.1 Business Overview
2.9.2 IBS-C Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Synthetic Biologics IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Teva Pharmaceutical Industries
2.10.1 Business Overview
2.10.2 IBS-C Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Pharmaceutical Industries IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Bama-Geve
2.11.1 Business Overview
2.11.2 IBS-C Drug Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bama-Geve IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Ferring BV
2.12.1 Business Overview
2.12.2 IBS-C Drug Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Ferring BV IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Ironwood Pharmaceuticals
2.13.1 Business Overview
2.13.2 IBS-C Drug Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Ironwood Pharmaceuticals IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Salix Pharmaceuticals
2.14.1 Business Overview
2.14.2 IBS-C Drug Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Salix Pharmaceuticals IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Norgine
2.15.1 Business Overview
2.15.2 IBS-C Drug Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Norgine IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Prometheus Laboratories
2.16.1 Business Overview
2.16.2 IBS-C Drug Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Prometheus Laboratories IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 Actavis Nordic
2.17.1 Business Overview
2.17.2 IBS-C Drug Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Actavis Nordic IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Albireo Pharma
2.18.1 Business Overview
2.18.2 IBS-C Drug Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Albireo Pharma IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Yuhan Corp
2.19.1 Business Overview
2.19.2 IBS-C Drug Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Yuhan Corp IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 Astrazeneca
2.20.1 Business Overview
2.20.2 IBS-C Drug Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Astrazeneca IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.21 The Menarini Group
2.21.1 Business Overview
2.2.2 IBS-C Drug Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 The Menarini Group IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.22 Ono Pharmaceutical
2.22.1 Business Overview
2.22.2 IBS-C Drug Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Ono Pharmaceutical IBS-C Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global IBS-C Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global IBS-C Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global IBS-C Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 IBS-C Drug Manufacturer Market Share in 2017
3.3.2 Top 6 IBS-C Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global IBS-C Drug Market Analysis by Regions
4.1 Global IBS-C Drug Sales, Revenue and Market Share by Regions
4.1.1 Global IBS-C Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global IBS-C Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America IBS-C Drug Sales and Growth Rate (2013-2018)
4.3 Europe IBS-C Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific IBS-C Drug Sales and Growth Rate (2013-2018)
4.5 South America IBS-C Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa IBS-C Drug Sales and Growth Rate (2013-2018)
5 North America IBS-C Drug by Countries
5.1 North America IBS-C Drug Sales, Revenue and Market Share by Countries
5.1.1 North America IBS-C Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America IBS-C Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States IBS-C Drug Sales and Growth Rate (2013-2018)
5.3 Canada IBS-C Drug Sales and Growth Rate (2013-2018)
5.4 Mexico IBS-C Drug Sales and Growth Rate (2013-2018)
6 Europe IBS-C Drug by Countries
6.1 Europe IBS-C Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe IBS-C Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe IBS-C Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany IBS-C Drug Sales and Growth Rate (2013-2018)
6.3 UK IBS-C Drug Sales and Growth Rate (2013-2018)
6.4 France IBS-C Drug Sales and Growth Rate (2013-2018)
6.5 Russia IBS-C Drug Sales and Growth Rate (2013-2018)
6.6 Italy IBS-C Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific IBS-C Drug by Countries
7.1 Asia-Pacific IBS-C Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific IBS-C Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific IBS-C Drug Revenue and Market Share by Countries (2013-2018)
7.2 China IBS-C Drug Sales and Growth Rate (2013-2018)
7.3 Japan IBS-C Drug Sales and Growth Rate (2013-2018)
7.4 Korea IBS-C Drug Sales and Growth Rate (2013-2018)
7.5 India IBS-C Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia IBS-C Drug Sales and Growth Rate (2013-2018)
8 South America IBS-C Drug by Countries
8.1 South America IBS-C Drug Sales, Revenue and Market Share by Countries
8.1.1 South America IBS-C Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America IBS-C Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil IBS-C Drug Sales and Growth Rate (2013-2018)
8.3 Argentina IBS-C Drug Sales and Growth Rate (2013-2018)
8.4 Colombia IBS-C Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa IBS-C Drug by Countries
9.1 Middle East and Africa IBS-C Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa IBS-C Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa IBS-C Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia IBS-C Drug Sales and Growth Rate (2013-2018)
9.3 UAE IBS-C Drug Sales and Growth Rate (2013-2018)
9.4 Egypt IBS-C Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria IBS-C Drug Sales and Growth Rate (2013-2018)
9.6 South Africa IBS-C Drug Sales and Growth Rate (2013-2018)
10 Global IBS-C Drug Market Segment by Type
10.1 Global IBS-C Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global IBS-C Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global IBS-C Drug Revenue and Market Share by Type (2013-2018)
10.2 Linaclotide Sales Growth and Price
10.2.1 Global Linaclotide Sales Growth (2013-2018)
10.2.2 Global Linaclotide Price (2013-2018)
10.3 Lubiprostone Sales Growth and Price
10.3.1 Global Lubiprostone Sales Growth (2013-2018)
10.3.2 Global Lubiprostone Price (2013-2018)
10.4 Osmotic Laxatives Sales Growth and Price
10.4.1 Global Osmotic Laxatives Sales Growth (2013-2018)
10.4.2 Global Osmotic Laxatives Price (2013-2018)
10.5 Stimulant Laxatives Sales Growth and Price
10.5.1 Global Stimulant Laxatives Sales Growth (2013-2018)
10.5.2 Global Stimulant Laxatives Price (2013-2018)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2013-2018)
10.6.2 Global Other Price (2013-2018)
11 Global IBS-C Drug Market Segment by Application
11.1 Global IBS-C Drug Sales Market Share by Application (2013-2018)
11.2 Hospital Pharmacies Sales Growth (2013-2018)
11.3 Retail Pharmacies Sales Growth (2013-2018)
11.4 Online Pharmacies Sales Growth (2013-2018)
12 IBS-C Drug Market Forecast (2018-2023)
12.1 Global IBS-C Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 IBS-C Drug Market Forecast by Regions (2018-2023)
12.2.1 North America IBS-C Drug Market Forecast (2018-2023)
12.2.2 Europe IBS-C Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific IBS-C Drug Market Forecast (2018-2023)
12.2.4 South America IBS-C Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa IBS-C Drug Market Forecast (2018-2023)
12.3 IBS-C Drug Market Forecast by Type (2018-2023)
12.3.1 Global IBS-C Drug Sales Forecast by Type (2018-2023)
12.3.2 Global IBS-C Drug Market Share Forecast by Type (2018-2023)
12.4 IBS-C Drug Market Forecast by Application (2018-2023)
12.4.1 Global IBS-C Drug Sales Forecast by Application (2018-2023)
12.4.2 Global IBS-C Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure IBS-C Drug Picture
Table Product Specifications of IBS-C Drug
Figure Global Sales Market Share of IBS-C Drug by Types in 2017
Table IBS-C Drug Types for
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
